Intravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of Onset (PROST-3)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Standard-of-Care-Controlled Phase III Clinical Trial of Intravenous Recombinant Human Prourokinase (rhPro-UK) for the Treatment of Acute Ischemic Stroke Within 4.5 to 24 Hours of Symptom Onset
This is a multicenter, randomized, double-blind, double-dummy, standard-of-care-controlled Phase III clinical trial to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in adult patients with acute ischemic stroke (AIS) within 4.5 to 24 hours of symptom onset, including wake-up stroke and unwitnessed stroke.Eligible patients with salvageable ischemic tissue confirmed by CT perfusion or MRI perfusion/diffusion imaging will be randomized in a 1:1 ratio to receive either intravenous rhPro-UK 35 mg plus oral aspirin enteric-coated tablet placebo, or intravenous rhPro-UK placebo plus oral aspirin enteric-coated tablets 100-300 mg (standard of care).The primary objective is to evaluate the efficacy of intravenous rhPro-UK compared with standard of care in achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment. A total of 978 participants (489 per arm) will be enrolled at multiple centers in China.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Design: This is a multicenter, randomized, double-blind, double-dummy, standard-of-care (SOC)-controlled Phase III trial conducted at multiple centers in China. Randomization is performed using a stratified block randomization method, stratified by planned mechanical thrombectomy (2 levels: yes; no), with participants assigned in a 1:1 ratio to the rhPro-UK group or the SOC group.Treatment: Eligible and randomized participants receive the assigned investigational product as soon as possible (actual treatment initiation must be >4.5 hours and <=24 hours after stroke onset). The rhPro-UK group receives an intravenous infusion of rhPro-UK 35 mg in normal saline (15 mg as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg by intravenous infusion/pump over 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg at the start of thrombolysis. The SOC group receives an intravenous infusion of rhPro-UK placebo (same regimen) plus oral aspirin enteric-coated tablets 100-300 mg. All investigational products are administered once only; subsequent clinical antiplatelet therapy should be initiated no earlier than 24 hours after completion of the investigational product administration.Study Duration: The total duration of participation for each participant is approximately 90 days, including a screening period (pre-thrombolysis, -24 hours to 0 hour), a treatment period (thrombolysis, 0 hour), and a follow-up period (24 hours, 72 hours, Day 7, Day 30, and Day 90 after the start of thrombolysis).Statistical Considerations: The study hypothesis is based on the primary estimand. Null hypothesis H0: p1/p2 <= 1; alternative hypothesis H1: p1/p2 > 1, where p1 is the proportion of participants with an mRS score of 0-1 at 90 days in the rhPro-UK group and p2 is that in the SOC group. One interim analysis is planned, using the Lan-DeMets spending function with O'Brien-Fleming efficacy boundaries; the two-sided type I error is controlled at 0.003 for the interim analysis and 0.049 for the final analysis, maintaining an overall two-sided type I error of 0.05.Committees: An Academic Committee will be established before trial initiation to ensure the scientific feasibility of the protocol and standardization of trial conduct. An independent Clinical Events Committee (CEC) will adjudicate the type and drug-relatedness of all-cause death events within 7 days after treatment, as well as symptomatic intracranial hemorrhage (sICH). A Data Monitoring Committee (DMC) will convene regularly or as needed to perform unblinded sample size re-estimation, review safety data, and advise the sponsor on whether to continue, suspend, or stop the trial, or adjust the sample size.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Yongjun Wang, MD, PhD
- Phone Number: +86 13911172565
- Email: Yongjunwang111@aliyun.com
Study Contact Backup
- Name: Chunjuan Wang, MD, PhD
- Phone Number: +86 18210100840
- Email: wangchunjuan@ncrcnd.org.cn
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- Beijing Tiantan Hospital, Capital Medical University
-
Contact:
- Yongjun Wang, MD, PhD
- Phone Number: +86 13911172565
- Email: Yongjunwang111@aliyun.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >=18 years, male or female;
- Time from stroke symptom onset to planned thrombolysis >4.5 hours and <=24 hours (including wake-up stroke and unwitnessed stroke); the time of symptom onset is defined as the time the patient was last known to be well;
- Proximal or distal occlusion/stenosis of the internal carotid artery, middle cerebral artery, anterior cerebral artery, or posterior cerebral artery confirmed by CTA or MRA, identified as the culprit vessel responsible for the current acute ischemic stroke;
- Salvageable ischemic tissue demonstrated on CT perfusion (CTP) or MRI PWI/DWI sequences (infarct core volume <70 mL; hypoperfusion-to-infarct core mismatch ratio >=1.8; mismatch volume >=15 mL);
- NIHSS score of 6 to 25 (inclusive);
- Pre-stroke mRS score <2;
- No significant improvement in stroke clinical manifestations before treatment (as assessed by the investigator);
- The patient or his/her legally authorized representative is willing to participate in the trial and agrees to sign the informed consent form.
Exclusion Criteria:
- Unable to complete CTP/CTA or PWI/DWI/MRA examination;
- Large cerebral infarction indicated by CT/MRI (infarct area larger than one-third of the middle cerebral artery territory);
- Intracranial hemorrhage shown on CT/MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/epidural hematoma, etc.);
- Previous history of intracranial hemorrhage;
- Major head trauma or ischemic stroke within the past 3 months;
- Intracranial tumor or giant intracranial aneurysm;
- Intracranial or intraspinal surgery within the past 3 months;
- Gastrointestinal or urinary tract bleeding within the past 3 weeks;
- Major surgery or severe trauma within the past 2 weeks (as assessed by the investigator);
- Arterial puncture at a non-compressible site within the past 1 week;
- Active internal bleeding;
- Aortic arch dissection;
- Bacterial endocarditis or pericarditis;
- Hypertension remaining uncontrolled despite active antihypertensive therapy, with a post-treatment systolic blood pressure still >185 mmHg or diastolic blood pressure still >110 mmHg;
- Acute bleeding tendency, including platelet count <100 x 10^9/L;
- Treatment with low-molecular-weight heparin or heparin within 24 hours;
- Use of thrombin inhibitors or factor Xa inhibitors within the past 48 hours;
- Currently taking oral anticoagulants with prothrombin time (PT) >15 seconds or international normalized ratio (INR) >1.7;
- Seizure at stroke onset, or coexisting psychiatric disorder precluding compliance;
- Blood glucose <2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL);
- Severe hepatic insufficiency, including liver failure, cirrhosis, portal hypertension (esophageal varices), or active hepatitis;
- Severe renal insufficiency (eGFR <30 mL/min/1.73 m^2);
- Any terminal illness with a life expectancy of less than 1 year;
- Known hypersensitivity to rhPro-UK, the active ingredient of aspirin, or any other components of the investigational products;
- Pregnant or lactating women;
- Participation in another clinical trial within the past 1 month;
- Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the trial;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: rhPro-UK Group
Participants receive an intravenous infusion of recombinant human prourokinase (rhPro-UK) 35 mg in normal saline (15 mg administered as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg administered by intravenous infusion/pump over the subsequent 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only. |
rhPro-UK 35 mg dissolved in normal saline, administered intravenously as a single dose: 15 mg slow intravenous bolus over 3 minutes, followed by 20 mg intravenous infusion/pump over 30 minutes. Treatment initiation must be >4.5 hours and <=24 hours after stroke onset. Oral placebo matching aspirin enteric-coated tablets, 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion). |
|
Active Comparator: Standard of Care (SOC) Group
Participants receive an intravenous infusion of rhPro-UK placebo in normal saline (same administration regimen as the rhPro-UK group), plus oral aspirin enteric-coated tablets 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only. |
Oral aspirin enteric-coated tablets 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion). Subsequent clinical antiplatelet therapy is initiated no earlier than 24 hours after completion of the investigational product administration. Placebo matching rhPro-UK for injection, dissolved in normal saline and administered intravenously with the same regimen as rhPro-UK (15 mg-equivalent slow intravenous bolus over 3 minutes, followed by 20 mg-equivalent intravenous infusion/pump over 30 minutes), single dose. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Participants Achieving a Favorable Functional Outcome (mRS 0-1)
Time Frame: 90 days after treatment
|
Description: Proportion of participants with a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment. |
90 days after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Distribution of mRS Scores
Time Frame: 90 days after treatment
|
Distribution of modified Rankin Scale (mRS) scores at 90 days after treatment |
90 days after treatment
|
|
Proportion of Participants Achieving Functional Independence (mRS 0-2)
Time Frame: 90 days after treatment
|
Proportion of participants with an mRS score of 0-2 at 90 days after treatment. |
90 days after treatment
|
|
Proportion of Participants With Early Neurological Improvement at 24 Hours
Time Frame: 24 hours after treatment
|
Proportion of participants with a decrease of >=4 points in the National Institutes of Health Stroke Scale (NIHSS) score from baseline, or an NIHSS score <=1, at 24 hours after treatment. |
24 hours after treatment
|
|
Proportion of Participants With Neurological Improvement at Day 7
Time Frame: 7 days after treatment
|
Proportion of participants with a decrease of >=4 points in NIHSS score from baseline, or an NIHSS score <=1, at 7 days after treatment. |
7 days after treatment
|
|
Change From Baseline in NIHSS Score at 24 Hours
Time Frame: Baseline and 24 hours after treatment
|
Change in NIHSS score from baseline at 24 hours after treatment. |
Baseline and 24 hours after treatment
|
|
Change From Baseline in NIHSS Score at Day 7
Time Frame: Baseline and 7 days after treatment
|
Change in NIHSS score from baseline at 7 days after treatment. |
Baseline and 7 days after treatment
|
|
Proportion of Participants With a Barthel Index of 95-100
Time Frame: 90 days after treatment
|
Proportion of participants with a Barthel Index score of 95-100 at 90 days after treatment. |
90 days after treatment
|
|
Proportion of Participants Achieving Reperfusion at 24 Hours
Time Frame: 24 hours after treatment
|
Proportion of participants achieving reperfusion at 24 hours after treatment, defined as a >90% reduction from baseline in the volume of tissue with tracer arrival time (Tmax) >6 seconds. |
24 hours after treatment
|
|
Proportion of Participants Achieving Good Reperfusion on Angiography Before Thrombectomy
Time Frame: Before mechanical thrombectomy (Day 0)
|
Proportion of participants achieving good reperfusion, defined as an expanded Thrombolysis in Cerebral Infarction (eTICI) grade of 2b50 or higher, on angiography before thrombectomy (assessed only in participants undergoing mechanical thrombectomy). |
Before mechanical thrombectomy (Day 0)
|
|
Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the SITS-MOST Definition
Time Frame: Within 36 hours after treatment
|
Incidence of symptomatic intracranial hemorrhage as defined by the SITS-MOST criteria. |
Within 36 hours after treatment
|
|
Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the ECASS III Definition
Time Frame: Within 7 days after treatment
|
Incidence of symptomatic intracranial hemorrhage as defined by the ECASS III criteria. |
Within 7 days after treatment
|
|
Incidence of All-Cause Mortality Within 7 Days
Time Frame: Within 7 days after treatment
|
Incidence of death from any cause within 7 days after treatment. |
Within 7 days after treatment
|
|
Incidence of All-Cause Mortality Within 90 Days
Time Frame: Within 90 days after treatment
|
Within 90 days after treatment
|
|
|
Incidence of Major Bleeding Events Within 7 Days
Time Frame: Within 7 days after treatment
|
Within 7 days after treatment
|
|
|
Incidence of Intracranial Hemorrhage Events Within 7 Days
Time Frame: Within 7 days after treatment
|
Within 7 days after treatment |
Within 7 days after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TSL-BIO2601-AIS24-Ⅲ
- NMPA IND No. (Other Identifier: 2026LP02152)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.